Halozyme Therapeutics

Youtube Subscribe

Open: 40.5 Close: 39.76 Change: -0.74

The 6 top things that an AI found about Halozyme Therapeutics Stock and you do not know…

Are looking for the most relevant information about Halozyme Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Halozyme Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: company, Halozyme, Therapeutics, HALO, biopharmaceutical, focus, development, and the most common words in the summary are: therapeutic, inc, halozyme, nasdaq, biotechnology, unlock, cidara, . One of the sentences in the summary was: The company is expected to report cash flow growth of 24.2% …

Concept Map

Semantic Network

Stock Summary

Halozyme Therapeutics, Inc. researches, develops, and commercializes proprietary enzymes and devices. Company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery.

Today's Summary

Halozyme Therapeutics (HALO) is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company is expected to report cash flow growth of 24.2% this year.

Today's News

Halozyme Therapeutics (HALO) is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company is expected to report cash flow growth of 24.2% this year.

Stock Profile

"Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California."

Keywords

This document will help you to evaluate Halozyme Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Halozyme Therapeutics are: company, Halozyme, Therapeutics, HALO, biopharmaceutical, focus, development, and the most common words in the summary are: therapeutic, inc, halozyme, nasdaq, biotechnology, unlock, cidara, . One of the sentences in the summary was: The company is expected to report cash flow growth of 24.2% this year.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #inc #halozyme #nasdaq #biotechnology #unlock #cidara.

Read more →

Youtube Subscribe

---